|Bid||87.38 x 900|
|Ask||89.90 x 1200|
|Day's Range||86.41 - 90.64|
|52 Week Range||31.11 - 92.60|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1. Receipt of the option notice earns Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) a $10 million option exercise fee. Janssen will now have all rights to develop and commercialize ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead's proprietary Targeted RNAi Molecule platform. "The collaboration with Janssen, which was executed in 2018, for ARO-HBV against chronic hepatitis B infection, and potentially three additional programs, has been highly productive and collaborative," said Chris Anzalone, President & CEO at Arrowhead. Price Action: JNJ shares are down 0.22% at $170.02 during the premarket session on the last check Tuesday. ARWR closed at $73.05 on Monday. See more from BenzingaClick here for options trades from BenzingaUS Poised To Dispatch 20M Additional COVID-19 Shots To Countries In Need: CNBCJ&J Cuts This Week's COVID-19 Vaccine Deliveries For EU By Half: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
How far off is Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) from its intrinsic value? Using the most recent...
ARWR earnings call for the period ending March 31, 2021.